Can tiny needles boost hair growth in balding men?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male subjects aged 18-55 years. * Diagnosed with androgenetic alopecia (AGA) * Hamilton-Norwood hair-loss grade: Ⅲ vertex, Ⅳ, Ⅴ, or Ⅵ. * Willing to receive scalp photography for assessment, and maintain consistent hairstyle, hair color and hair length at each follow-up visit. * Understand the trial objectives, voluntarily provide written informed consent, and be willing and able to comply with the study protocol including scheduled follow-up visits and outcome evaluations. Exclusion Criteria: * Presence of other hair-loss disorders, including telogen effluvium, alopecia areata, lichen planopilaris, discoid lupus erythematosus, tinea capitis, and chemotherapy- or radiotherapy-induced alopecia. * Subjects with prior anti-hair-loss treatments: oral finasteride or dutasteride within 1 year before screening; other oral or topical hair-growth-promoting agents (e.g., minoxidil) within 6 months before screening; physical therapies for hair loss within 6 months before screening, including low-level laser therapy, microneedling, fractional laser, injection of PRP/PRF/CGF, scalp botulinum toxin injection; hair-growth-promoting cosmetic hair-care products, nutritional supplements, medicinal shampoos, serums or solutions that may interfere with efficacy evaluation within 1 month before screening; prior hair-transplantation surgery or hair-extension history. * Major surgery within 3 months planned major surgery during the trial period. * Participation in other drug or medical-device clinical trials within 3 months prior to screening. * Hair perming and/or hair dyeing within 3 months prior to screening. * Uncontrolled chronic or systemic diseases (e.g., hypertension, diabetes, bleeding disorders, severe infection, immune-system diseases, malignancy, hepatitis, thyroid disorders). * Co-existing diseases affecting hair growth, such as connective-tissue diseases, inflammatory bowel disease, moderate-to-severe anemia, significant weight loss (\>5 kg within 3 months). * Keloid predisposition: history of keloid/hypertrophic scars or clinically confirmed hypertrophic scars/keloids at any body site. * Known allergy to any components of microneedling devices or minoxidil. * Psychiatric disorders or emotional instability. * Any other conditions that, in the investigator's opinion, make the subject unsuitable for trial participation.